Raygenome Labs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 24-12-2024
- Paid Up Capital ₹ 8.75 M
as on 24-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -80.70%
(FY 2022)
- Profit 139.89%
(FY 2022)
- Ebitda 613.75%
(FY 2022)
- Net Worth 49.29%
(FY 2022)
- Total Assets -61.71%
(FY 2022)
About Raygenome Labs
The Corporate was formerly known as Megavision Life Sciences Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 8.75 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Mulay, Poonam Nigam, Alok Deodhar, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999PN2016PTC165849
- Company No.
165849
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2016
- Date of AGM
22 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Raygenome Labs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alok Deodhar  | Director | 21-Sep-2020 | Current |
| Anand Mulay | Director | 01-Aug-2022 | Current |
| Poonam Nigam | Director | 14-Jun-2024 | Current |
| Aniket Ausekar | Director | 10-Jun-2022 | Current |
Financial Performance of Raygenome Labs.
Raygenome Labs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 80.7% decrease. The company also saw a substantial improvement in profitability, with a 139.89% increase in profit. The company's net worth Soared by an impressive increase of 49.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raygenome Labs?
In 2022, Raygenome Labs had a promoter holding of 95.41% and a public holding of 4.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Evolvus Technologies Private LimitedActive 12 years 11 monthsAnand Mulay, Alok Deodhar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Raygenome Labs?
Unlock and access historical data on people associated with Raygenome Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raygenome Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raygenome Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
